BRIEF published on 02/20/2026 at 07:05, 6 months 20 days ago Le rapport annuel 2025 de BB Biotech met en lumière d'importants résultats financiers. Rapport Annuel BB Biotech Valeur Du Portefeuille Rendements Pour Les Actionnaires Gains Financiers
BRIEF published on 02/20/2026 at 07:05, 6 months 20 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
PRESS RELEASE published on 02/20/2026 at 07:00, 6 months 20 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 6 months 20 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
BRIEF published on 01/23/2026 at 07:05, 7 months 20 days ago BB Biotech AG Reports Significant Profit for 2025 Investment Company BB Biotech AG Drug Developers 2025 Profit Share Price Development
BRIEF published on 01/23/2026 at 07:05, 7 months 20 days ago BB Biotech AG annonce des bénéfices importants pour 2025 BB Biotech AG Société D'investissement Développeurs De Médicaments Bénéfices 2025 Évolution Du Cours De L'action
BRIEF published on 01/23/2026 at 07:05, 7 months 20 days ago BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal Dividend Proposal Share Performance BB Biotech Biotech Investment 2025 Financial Results
BRIEF published on 01/23/2026 at 07:05, 7 months 20 days ago BB Biotech annonce des résultats préliminaires solides pour 2025 et une proposition de dividende Proposition De Dividende BB Biotech Performance Des Actions Résultats Financiers 2025 Investissement En Biotechnologie
PRESS RELEASE published on 01/23/2026 at 07:00, 7 months 20 days ago EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit BB Biotech AG closes the 2025 fiscal year with a profit of approximately CHF 578 million, reflecting share price development. Full report on Feb 20, 2026 BB Biotech AG Profit 2025 Fiscal Year Share Price Development CHF 578 Million
PRESS RELEASE published on 01/23/2026 at 07:00, 7 months 20 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
Published on 09/12/2026 at 02:35, 11 hours 26 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 1 minute ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 56 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 36 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 1 minute ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 31 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 46 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 51 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 16 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 46 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
